Promoter dependence of plasmid-pluronics targeted α galactosidase A expression in skeletal muscle of fabry mice

Molecular Therapy

Volumn 12, Issue 5, 2005, Pages 985-990

  Lavigne, Matthieu D ^a   Pohlschmidt, Marita ^b   Novo, Javier F ^b   Higgins, Bernard ^a   Alakhov, Valery ^c   Lochmuller, Hanns ^d   Sakuraba, Hitoshi ^e   Goldspink, Geoffrey ^b   MacDermot, Kay ^f   Górecki, Dariusz C ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Supratek Pharma Inc   (Canada)

^d UNIVERSITY OF MUNICH   (Germany)

^e TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^f Kennedy Galton Centre   (United Kingdom)

Author keywords

galactosidase A; CMV promoter; Fabry disease gene therapy; Immune response; Immunosuppression; MCK promoter; Plasmid vector; Pluronic SP1017

Indexed keywords

ALPHA GALACTOSIDASE; PLASMID DNA; PLASMID VECTOR; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FABRY DISEASE; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PROMOTER REGION; SKELETAL MUSCLE;

ALPHA-GALACTOSIDASE; ANIMALS; ANTIBODIES; CD8-POSITIVE T-LYMPHOCYTES; FABRY DISEASE; GENE THERAPY; GENETIC VECTORS; MICE; MUSCLE, SKELETAL; PLASMIDS; PROMOTER REGIONS (GENETICS);

ANIMALIA; CUCUMBER MOSAIC VIRUS;

EID: 27744437341     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.02.032     Document Type: Article

References (27)

1. K.D. MacDermot A. Holmes and A.H. Miners Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males J. Med. Genet. 38 2001 750-760
2. T. Ohshima et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice Proc. Natl. Acad. Sci. USA 96 1999 6423-6427
3. R.J. Ziegler et al. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer Hum. Gene Ther. 10 1999 1667-1682
4. F. Xu Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA J. Gene. Med. 7 2004 171-178
5. Y.A. Ioannou K.M. Zeidner R.E. Gordon and R.J. Desnick Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice Am. J. Hum. Genet. 68 2001 14-25
6. C.M. Eng et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease N. Engl. J. Med. 345 2001 9-16
7. T. Ohshima et al. α-Galactosidase A deficient mice: A model of Fabry disease Proc. Natl. Acad. Sci. USA 94 1997 2540-2544
8. P. Lemieux et al. A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle Gene Ther. 7 2000 986-991
9. M. Donoghue H. Ernst B. Wentworth B. Nadal-Ginard and N. Rosenthal A muscle-specific enhancer is located at the 3′ end of the myosin light-chain 1/3 gene locus Genes Dev. 2 1988 1779-1790
10. L. Hennighausen and B. Fleckenstein Nuclear factor 1 interacts with five DNA elements in the promoter region of the human cytomegalovirus major immediate early gene EMBO J. 5 1986 1367-1371
11. N. Larochelle et al. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer Gene Ther. 4 1997 465-472
12. A. Abe et al. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation J. Clin. Invest. 105 2000 1563-1571
13. H. Takahashi et al. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer Proc. Natl. Acad. Sci. USA 99 2002 13777-13782
14. J. Park et al. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer Proc. Natl. Acad. Sci. USA 100 2003 3450-3454
15. H. Sbai J. Schneider A.V. Hill and R.G. Whalen Role of transfection in the priming of cytotoxic T-cells by DNA-mediated immunization Vaccine 20 2002 3137-3147
16. D. Hartigan-O'Connor C.J. Kirk R. Crawford J.J. Mule and J.S. Chamberlain Immune evasion by muscle-specific gene expression in dystrophic muscle Mol. Ther. 4 2001 525-533
17. M.A. Kutzler and D.B. Weiner Developing DNA vaccines that call to dendritic cells J. Clin. Invest. 114 2004 1241-1244
18. R. Schiffmann et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease Proc. Natl. Acad. Sci. USA 97 2000 365-370
19. A. Bojak D. Hammer H. Wolf and R. Wagner Muscle specific versus ubiquitous expression of Gag based HIV-1 DNA vaccines: A comparative analysis Vaccine 20 2002 1975-1979
20. J.A. Villadangos and H.L. Ploegh Proteolysis in MHC class II antigen presentation: Who's in charge? Immunity 12 2000 233-239
21. M. Yasuda J. Shabbeer M. Osawa and R.J. Desnick Fabry disease: Novel alpha-galactosidase A 3′-terminal mutations result in multiple transcripts due to aberrant 3′-end formation Am. J. Hum. Genet. 73 2003 162-173
22. T. Okumiya S. Ishii R. Kase S. Kamei H. Sakuraba and Y. Suzuki Alpha-galactosidase gene mutations in Fabry disease: Heterogeneous expressions of mutant enzyme proteins Hum. Genet. 95 1995 557-561
23. V. Alakhov E. Klinski P. Lemieux G. Pietrzynski and A.V. Kabanov Block copolymeric biotransport carriers as versatile vehicles for drug delivery Expert Opin. Biol. Ther. 1 2001 583-602
24. A.V. Kabanov E.V. Batrakova S. Sriadibhatla Z. Yang D.L. Kelly and V. Alakhov Polymer genomics: Shifting the gene and drug delivery paradigms J. Controlled Release 101 2005 257-259
25. F.J. Novo D.C. Gorecki G. Goldspink and K.D. MacDermot Gene transfer and expression of human alpha-galactosidase from mouse muscle in vitro and in vivo Gene Ther. 4 1997 488-492
26. K.E. Wells et al. Immune responses, not promoter inactivation, are responsible for decreased long-term expression following plasmid gene transfer into skeletal muscle FEBS Lett. 407 1997 164-168
27. A. Ferrer K.E. Wells and D.J. Wells Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy Gene Ther. 7 2000 1439-1446